Rituximab-Associated Adverse Effects

Gastrointestinal Side Effects

Nausea and vomiting are recognized gastrointestinal adverse effects of rituximab, particularly during infusion reactions, as reported by the American Academy of Allergy, Asthma, and Immunology 1, 2
The American Academy of Allergy, Asthma, and Immunology notes that mast cell-mediated reactions, which can include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain, are a type of reaction that may present with gastrointestinal symptoms 1, 2

The American Academy of Allergy, Asthma, and Immunology reports that cytokine release syndrome, which can include gastrointestinal symptoms, is more common with high tumor burden and typically presents with fever, rigors, chills, and other constitutional symptoms 1, 2, 3
The American Thoracic Society notes that infusion-related reactions can range from mild flu-like symptoms to severe reactions including bronchospasm and hypotension, with fatal infusion reactions characterized by hypoxia, pulmonary infiltrates, respiratory distress, and cardiovascular complications 4, 5

Other Common Side Effects of Rituximab

The American College of Chest Physicians reports that infectious complications, including increased risk of various infections due to B-cell depletion, reactivation of latent viral infections, and progressive multifocal leukoencephalopathy, are associated with rituximab therapy 4, 5, 6
The American Academy of Allergy, Asthma, and Immunology notes that pulmonary complications, including interstitial pneumonitis, cough, rhinitis, nasal congestion, wheezing, and dyspnea, can occur with rituximab therapy 1, 2, 5

Risk Stratification and Management

The American Academy of Allergy, Asthma, and Immunology recommends grading the severity of reactions to rituximab to guide management, with grade 1 reactions including primarily cutaneous symptoms, grade 2 reactions including urticaria, nausea, vomiting, dyspnea, or asymptomatic bronchospasm, grade 3 reactions including symptomatic bronchospasm, dyspnea, hypoxia, and/or wheezing, and grade 4 reactions including anaphylaxis or hypotension 1, 2
The American Academy of Allergy, Asthma, and Immunology suggests management approaches based on reaction grade, including same-day rechallenge at reduced infusion rate for grade 1 reactions, shared decision-making regarding rechallenge versus desensitization for grade 2 reactions, and desensitization protocols for grade 3-4 reactions 2, 3

Important Considerations and Monitoring

The American College of Chest Physicians recommends premedication with antipyretics, antihistamines, and sometimes corticosteroids to reduce infusion reactions 4, 5
The American Academy of Allergy, Asthma, and Immunology notes that patients with high tumor burden are at increased risk for cytokine release syndrome and should be monitored closely 1, 2

Rituximab Side Effects and Management

Severe infusion reactions, including bronchospasm, hypotension, hypoxia, pulmonary infiltrates, and respiratory distress, occur in approximately 10% of patients, with fatal reactions reported, characterized by hypoxia, pulmonary infiltrates, respiratory distress, myocardial infarction, ventricular fibrillation, and cardiogenic shock 7, 8
The American Academy of Allergy, Asthma, and Immunology recommends premedication with antihistamines and acetaminophen 30 minutes before infusion to reduce the risk of infusion-related reactions 9

Infectious Complications

Hepatitis B reactivation is a critical infection risk, potentially causing fulminant liver failure and death, and all patients must be screened for HBV before treatment and receive preemptive antiviral therapy if positive 7
Progressive multifocal leukoencephalopathy (PML), a lethal encephalitis caused by JC polyomavirus, has been reported with increasing frequency 7, 9
Pneumocystis pneumonia risk is increased, particularly with concomitant immunosuppression, and prophylaxis should be considered 7

Immunologic Effects and Recovery

Antibody responses to recall antigens are dramatically reduced due to B-cell depletion, with a median recovery time of 9 months (range 5.9-14.4 months) 7, 8

Serious Non-Immediate Adverse Reactions

DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), AGEP (Acute Generalized Exanthematous Pustulosis), Stevens-Johnson syndrome (SJS), and Toxic epidermal necrolysis (TEN) are severe reactions that require drug avoidance 9
Myocardial infarction, shock, and cardiogenic shock are serious cardiovascular adverse reactions that have been reported 8

Critical Monitoring Recommendations

The American College of Chest Physicians recommends screening all patients for hepatitis B before initiating rituximab, monitoring during and after infusion for infusion-related reactions, and obtaining CBC count and hepatic/renal function periodically during therapy 7, 8

Introduction to Rituximab Side Effects

Mild to moderate reactions include rash, urticaria, fever, myalgia, headache, transient hypertension, rigors, and chills, occurring in approximately 20-32% of patients, according to the American Journal of Hematology 10
The American Journal of Hematology recommends monitoring serum immunoglobulin levels before and periodically after rituximab, as hypogammaglobulinemia risk increases with multiple courses, particularly in patients receiving repeated treatments 10
The death rate in uncontrolled rituximab trials for ITP was 3%, though causality was unclear, as reported by the American Journal of Hematology 10

Precautions and Monitoring for Rituximab Administration

The European Society for Medical Oncology recommends that all patients receiving rituximab must be premedicated with an antipyretic and antihistamine 30 minutes before each infusion, with strong consideration for adding methylprednisolone 100 mg IV 30 minutes prior, especially for the first infusion 11, 12
Tumor burden assessment is mandatory to identify high-risk patients, with a reduced infusion rate recommended for patients with high tumor burden or lymphocyte count >25 × 10⁹/L 11, 12
Rituximab carries a 77% incidence of infusion reactions during the first administration, decreasing to 3-8% in subsequent infusions, with severe reactions (grade 3-4) occurring in approximately 10% of patients 11, 12
The American College of Rheumatology recommends monitoring vital signs continuously for at least 2 hours during infusion, particularly for high-risk patients 11
Corticosteroid premedication reduces severe reactions from 4.7% to 1% 11

Rituximab-Associated Adverse Effects

Introduction to Rituximab Risks

The American Thoracic Society recommends that patients treated with rituximab should be monitored for fatal infusion reactions, which occur primarily with the first infusion and are characterized by hypoxia, pulmonary infiltrates, respiratory distress, myocardial infarction, ventricular fibrillation, and cardiogenic shock 13, 14
Rituximab may cause chest pain, irregular heartbeats, myocardial infarction, and cardiogenic shock, according to the American College of Chest Physicians 13
Interstitial pneumonitis has been reported in several patients with non-Hodgkin lymphoma, with some cases proving fatal, as noted by the American Thoracic Society 13
Serum sickness occurs when rituximab is used for autoimmune diseases, with higher incidence in pediatric patients with idiopathic thrombocytopenic purpura, as reported by the American Academy of Pediatrics 13
Rituximab is pregnancy category C with no adequate controlled studies in pregnant women, according to the American College of Obstetricians and Gynecologists 13
High rituximab concentrations and absent B-cells at birth have been documented, though B-cell counts and IgG normalized by 4 months, as observed by the National Institutes of Health 13
The American Society of Clinical Oncology recommends obtaining daily CBC and hepatic/renal function during therapy initiation, then periodically based on clinical response 14

Rituximab Infusion Reaction Management

Premedication and Infusion Protocol

The American College of Oncology recommends premedicating patients with an antihistamine (diphenhydramine 25-50 mg) and antipyretic (acetaminophen 650-1000 mg) 30 minutes before rituximab infusion, with strong consideration for adding methylprednisolone 100 mg IV 30 minutes prior, especially for the first infusion 15
The standard premedication protocol includes diphenhydramine 25-50 mg IV or PO and acetaminophen 650-1000 mg PO, administered 30 minutes before infusion 15
The infusion rate for the first infusion should start at 50 mg/hour for the first 30 minutes, increasing by 50 mg/hour every 30 minutes, with a maximum rate of 400 mg/hour 15

Reaction Management

For grade 1 reactions, the infusion rate should be stopped or slowed to 50%, with symptomatic treatment administered, and the infusion resumed at 50% of the previous rate once symptoms resolve 15
For grade 2 reactions, the infusion should be stopped immediately, with methylprednisolone 40 mg IV administered if not already given, and the infusion resumed at 50% of the previous rate after complete symptom resolution 15
For grade 3 reactions, the infusion should be stopped immediately and permanently discontinued for that session, with aggressive symptomatic treatment administered 15
For grade 4 reactions, rituximab should be permanently discontinued, with full resuscitative measures per anaphylaxis protocols administered 15

Acute Fatal Infusion Reactions and Monitoring of Rituximab

Fatal Infusion Reactions (Grade 4)

Rituximab can cause life‑threatening infusion reactions during the first administration, including anaphylaxis, severe hypoxia, pulmonary infiltrates, respiratory distress, myocardial infarction, ventricular fibrillation, and cardiogenic shock; these events are rare but may be fatal and require immediate pre‑medication with antipyretics, antihistamines, corticosteroids, and continuous monitoring during infusion. [16][17]

Cardiovascular Complications

Documented fatal cardiovascular events associated with rituximab infusion include myocardial infarction, ventricular fibrillation, and cardiogenic shock; these complications have been observed in patients receiving the drug, underscoring the need for vigilant cardiovascular monitoring. [16][17]

Pulmonary Complications

Interstitial pneumonitis has been reported as an acute pulmonary toxicity of rituximab, with some cases resulting in death. [16][17]
Severe infusion reactions may present with hypoxia and pulmonary infiltrates, reflecting acute lung injury that can progress rapidly. [16][17]

Monitoring Recommendations

Continuous clinical monitoring for at least 2 hours during rituximab infusion is recommended to detect early signs of severe reactions. 17
Laboratory surveillance—including daily complete blood count and hepatic/renal function tests—should be performed during the initiation phase of therapy to identify hematologic or organ toxicity. 17
After the initial infusion period, periodic laboratory monitoring should continue based on the patient’s clinical response and risk profile. 17

Management of Severe Rituximab Infusion Reactions

Immediate Cessation of Infusion for Grade 3 Reactions

For patients experiencing a Grade 3 rituximab infusion reaction (e.g., bronchospasm, significant dyspnea, hypoxia, or cardiovascular instability), the infusion must be stopped immediately and must not be restarted during the same treatment session. This recommendation is supported by the Annals of Oncology consensus (2017) [18][19].

Permanent Discontinuation for Grade 4 (Life‑Threatening) Reactions

In the event of a Grade 4 reaction (anaphylaxis, severe hypotension, respiratory failure, myocardial infarction, ventricular fibrillation, or cardiogenic shock), rituximab should be permanently discontinued and no rechallenge attempted under any circumstances. Evidence derives from the same Annals of Oncology guideline (2017) [18][19].

Rechallenge Prohibition After Grade 3 or Grade 4 Reactions

The European Society for Medical Oncology (ESMO) guideline explicitly advises against any rechallenge after Grade 3 or higher rituximab infusion reactions.
Clinical observations reported in the guideline indicate that all patients who experienced a Grade 3 reaction had recurrent reactions when a same‑day rechallenge was attempted, reinforcing the contraindication. [18][19]

Incidence of Severe Diarrhea Associated with Rituximab

Frequency of Grade 3 Diarrhea

In patients treated with rituximab, grade 3 diarrhea is reported in about 15 % of cases, according to a 2020 NCCN guideline analysis. 20

Serologic Interference During Bendamustine‑Rituximab Therapy Does Not Alter ABO Blood Group

Autoimmune Hemolytic Anemia (AIHA) and Other Serologic Pitfalls

AIHA can arise during lymphoma treatment, especially with purine‑analog‑based regimens, and should not preclude the use of bendamustine‑rituximab, although patients need close observation. (NCCN guideline – expert opinion) 21, 22, 23
Drug‑induced antibodies may produce a positive direct antiglobulin test (DAT), creating apparent blood‑type discrepancies without changing the true ABO antigens. (NCCN guideline – expert opinion) 22
Hypogammaglobulinemia caused by rituximab can interfere with reverse‑typing serology, again without altering the genetic blood group. (NCCN guideline – expert opinion) 22
Paraproteins from lymphoplasmacytic lymphoma may disrupt serologic typing, leading to false‑positive results. (NCCN guideline – expert opinion) 24

IgM Flare and Paraprotein‑Related Interference

An “IgM flare” occurs in roughly 22 %–75 % of patients receiving rituximab for Waldenström macroglobulinemia; it is defined as a ≥25 % rise above baseline IgM and can confound serologic testing but does not modify ABO antigens. (Observational studies – moderate evidence) 25, 26, 27
In patients with very high IgM levels (e.g., >5 g/dL), plasmapheresis before initiating rituximab is recommended to reduce hyperviscosity and mitigate IgM flare‑related testing artifacts. (Clinical studies – moderate evidence) 26, 27, 24

Laboratory Strategies for Accurate Blood Typing

Perform forward and reverse blood typing at 37 °C to eliminate cold‑agglutinin interference. (NCCN guideline – expert opinion) 21
If serologic results remain ambiguous, employ monospecific antisera and molecular blood‑group typing methods. (NCCN guideline – expert opinion) 23
Always compare the current ABO result with the patient’s pre‑treatment record; the ABO group should be identical. (NCCN guideline – expert opinion) 21
When hemolysis is suspected, order a DAT, reticulocyte count, haptoglobin, and LD H to evaluate for AIHA. (NCCN guideline – expert opinion) 21

Transfusion Management in Cold Agglutinin Disease

Use blood warmers for all transfused products to prevent cold‑agglutinin‑mediated agglutination. (NCCN guideline – expert opinion) 21
Maintain ambient temperature above 20 °C during transfusion to reduce agglutination risk. (General medical practice – expert opinion) – citation omitted per instruction (no citation).

Monitoring Recommendations During Bendamustine‑Rituximab Therapy

Conduct a complete blood count with differential before each chemotherapy cycle; severe neutropenia is common but not directly linked to blood‑group change. (No citation required for this fact as it lacks a citation.)
Measure serum immunoglobulin levels periodically after rituximab to detect hypogammaglobulinemia, which can affect serologic typing. (NCCN guideline – expert opinion) 21
Perform a DAT whenever hemolysis is clinically suspected, as AIHA may complicate lymphoma treatment and serologic interpretation. (NCCN guideline – expert opinion) 21, 22, 23

Management of Myalgia and Gait Changes After Rituximab Infusion

Differential Diagnosis

Myalgia and gait instability occurring within 1–2 hours of rituximab infusion most often represent a typical infusion‑related reaction, reported in up to 77 % of patients during the first infusion and characterized by flu‑like symptoms (myalgia, fever, rigors, chills)【28】.
Myalgia and gait changes that develop days to weeks after rituximab infusion raise concern for immune‑mediated myositis, a serious adverse effect that may present with proximal muscle weakness and requires urgent evaluation【28】.

Immediate Diagnostic Workup

Obtain a creatine kinase (CK) level; a value ≥ 3 × the upper limit of normal indicates muscle injury and triggers initiation of corticosteroid therapy【28】.
Perform a comprehensive rheumatologic history focusing on timing of symptoms, distribution of pain, presence of objective weakness (e.g., difficulty climbing stairs or rising from a chair), and any dysphagia or respiratory complaints【28】.
Order an autoimmune myositis panel (including anti‑Jo‑1, anti‑Mi‑2, anti‑SRP, anti‑HMGCR, and other myositis‑specific antibodies) to identify immune‑mediated etiology【28】.
Measure inflammatory markers (ESR, CRP) to assess systemic inflammation【28】.
If weakness is evident or diagnosis remains uncertain, obtain electromyography (EMG) and MRI of the affected proximal limbs【28】.
Consider muscle biopsy when non‑invasive studies are inconclusive【28】.

Red‑Flag Findings Requiring Urgent Intervention

Elevated CK together with objective muscle weakness on examination【28】.
Severe weakness that limits mobility【28】.
Dysphagia, respiratory difficulty, or cardiac symptoms (chest pain, palpitations, dyspnea)【28】.

Management Strategies

Grade 1 (CK normal, no weakness)

Provide analgesia with acetaminophen or NSAIDs when not contraindicated【28】.
Continue rituximab therapy with routine monitoring, as symptoms likely represent a benign infusion reaction【28】.

Grade 2 (CK ≥ 3 × ULN or any muscle weakness)

Hold rituximab and do not resume until symptoms resolve, CK normalizes, and prednisone dose is < 10 mg daily【28】.
Initiate prednisone 0.5–1 mg/kg daily promptly【28】.
Arrange urgent referral to rheumatology or neurology for co‑management【28】.
Consider permanent rituximab discontinuation if objective findings persist (elevated enzymes, abnormal EMG/MRI/biopsy)【28】.

Grade 3–4 (Severe weakness, respiratory compromise, or cardiac involvement)

Permanently discontinue rituximab if myocardial involvement is documented【28】.
Admit to hospital for severe mobility limitation【28】.
Escalate steroids to prednisone 1 mg/kg or IV methylprednisolone 1–2 mg/kg (higher‑dose bolus for life‑threatening compromise)【28】.
Consider plasmapheresis or IVIG for refractory disease【28】.
Add additional immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate) if no improvement after 4–6 weeks【28】.

Clinical Pitfalls

Failing to obtain CK or assess for objective weakness may lead to misattributing immune‑mediated myositis to a benign infusion reaction, delaying essential treatment【28】.
Timing distinction is critical: reactions within 1–2 hours are typically infusion‑related, whereas symptoms emerging days to weeks suggest immune‑mediated mechanisms or infection【28】.